Entera Bio (ENTX) Stock Price, News & Analysis

Company Overview

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Key Stats

• Today's Range: $2.27 to $2.58
• 50-Day Range: $1.60 to $2.40
• 52-Week Range: $1.41 to $2.79
• Volume: 157,921 shs
• Average Volume: 82,050 shs
• Market Capitalization: $109.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

Entera Bio Stock Analysis - MarketRank™

Entera Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 491st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Entera Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Entera Bio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Entera Bio are expected to decrease in the coming year, from ($0.28) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entera Bio is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entera Bio is -9.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entera Bio has a P/B Ratio of 6.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entera Bio does not currently pay a dividend.

Dividend Growth

Entera Bio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently decreased by 13.12%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.93

News Sentiment

Entera Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Entera Bio this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entera Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.90% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.11% of the stock of Entera Bio is held by institutions.

ENTX Stock Analysis - Frequently Asked Questions

How have ENTX shares performed this year?

Entera Bio's stock was trading at $2.12 at the start of the year. Since then, ENTX shares have increased by 13.2% and is now trading at $2.40.
View the best growth stocks for 2025 here.

How were Entera Bio's earnings last quarter?

Entera Bio Ltd. (NASDAQ:ENTX) announced its earnings results on Friday, March, 28th. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The company earned $0.04 million during the quarter, compared to analyst estimates of $0.04 million.

When did Entera Bio IPO?

Entera Bio (ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at a price of $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

How do I buy shares of Entera Bio?

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Entera Bio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entera Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 3/28/2025
• Today: 4/26/2025
• Next Earnings (Estimated): 5/09/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ENTX
• CIK: 1638097
• Web: www.enterabio.com
• Phone: (722) 532-7151
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $10.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +316.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,890,000.00
• Net Margins: N/A
• Pretax Margin: -9,270.71%
• Return on Equity: -107.24%
• Return on Assets: -92.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.61
• Quick Ratio: 6.61

Sales & Book Value

• Annual Sales: $181,000.00
• Price / Sales: 602.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.36 per share
• Price / Book: 6.67

Miscellaneous

• Outstanding Shares: 45,421,000
• Free Float: 31,884,000
• Market Cap: $109.01 million
• Optionable: Optionable
• Beta: 1.47